SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

Autolus Therapeutics plc

(Name of Issuer)

American Depositary Shares and Ordinary Shares, nominal value £0.000042 per share

(Title of Class of Securities)

05280R 100**

(CUSIP Number)

December 31, 2020

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

**

There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.” Each American Depositary Share represents the right to receive one ordinary share.

 

 

 


SCHEDULE 13G/A      
CUSIP No. 05280R 100      

 

  1    

  Names of Reporting Person:

 

  Syncona Portfolio Limited

  2  

  Check the appropriate box if a member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Guernsey

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

     5     

  Sole Voting Power

 

  0

   6   

  Shared Voting Power

 

  15,955,734 (1)

   7   

  Sole Dispositive Power

 

  0

   8   

  Shared Dispositive Power

 

  15,955,734 (1)

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  15,955,734 (1)

10  

  Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 

11  

  Percent of class represented by amount in row (9)

 

  30.5% (2)

12  

  Type of Reporting Person (See Instructions)

 

  CO

 

(1)

Consists of 12,180,333 ordinary shares and 3,775,401 American Depositary Shares (“ADSs”) held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the “Ordinary Shares”.

(2)

Based on 52,298,876 Ordinary Shares outstanding as of September 30, 2020 as reported in the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2020.

 

Page 2 of 9


   SCHEDULE 13G   
CUSIP No. 05280R 100      

 

  1    

  Names of Reporting Person:

 

  Syncona Holdings Limited

  2  

  Check the appropriate box if a member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Guernsey

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

     5     

  Sole Voting Power

 

  0

   6   

  Shared Voting Power

 

  15,955,734 (1)

   7   

  Sole Dispositive Power

 

  0

   8   

  Shared Dispositive Power

 

  15,955,734 (1)

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  15,955,734 (1)

10  

  Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 

11  

  Percent of class represented by amount in row (9)

 

  30.5% (2)

12  

  Type of Reporting Person (See Instructions)

 

  CO

 

(1)

Consists of 12,180,333 ordinary shares and 3,775,401 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer.

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 52,298,876 Ordinary Shares outstanding as of September 30, 2020 as reported in the Issuer’s report on Form 6-K filed with the SEC on November 5, 2020.

 

Page 3 of 9


   SCHEDULE 13G   
CUSIP No. 05280R 100      

 

  1    

  Names of Reporting Person:

 

  Syncona Investment Management Limited

  2  

  Check the appropriate box if a member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  United Kingdom

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

     5     

  Sole Voting Power

 

  0

   6   

  Shared Voting Power

 

  15,955,734 (1)

   7   

  Sole Dispositive Power

 

  0

   8   

  Shared Dispositive Power

 

  15,955,734 (1)

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  15,955,734 (1)

10  

  Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 

11  

  Percent of class represented by amount in row (9)

 

  30.5% (2)

12  

  Type of Reporting Person (See Instructions)

 

  CO

 

(1)

Consists of 12,180,333 ordinary shares and 3,775,401 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer.

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 52,298,876 Ordinary Shares outstanding as of September 30, 2020 as reported in the Issuer’s report on Form 6-K filed with the SEC on November 5, 2020.

 

Page 4 of 9


   SCHEDULE 13G   
CUSIP No. 05280R 100      

 

  1    

  Names of Reporting Person:

 

  Syncona Limited

  2  

  Check the appropriate box if a member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Guernsey

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

     5     

  Sole Voting Power

 

  0

   6   

  Shared Voting Power

 

  15,955,734 (1)

   7   

  Sole Dispositive Power

 

  0

   8   

  Shared Dispositive Power

 

  15,955,734 (1)

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  15,955,734 (1)

10  

  Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 

11  

  Percent of class represented by amount in row (9)

 

  30.5% (2)

12  

  Type of Reporting Person (See Instructions)

 

  CO

 

(1)

Consists of 12,180,333 ordinary shares and 3,775,401 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer.

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 52,298,876 Ordinary Shares outstanding as of September 30, 2020 as reported in the Issuer’s report on Form 6-K filed with the SEC on November 5, 2020.

 

Page 5 of 9


   SCHEDULE 13G   
CUSIP No. 05280R 100      

 

Item 1.

 

(a)

Name of Issuer: Autolus Therapeutics plc

 

(b)

Address of Issuer’s principal executive offices: Forest House, 58 Wood Lane, London W12 7RZ, United Kingdom

 

Item 2.

 

(a)

Name of reporting persons filing:

 

  (i)

Syncona Portfolio Limited;

 

  (ii)

Syncona Holdings Limited;

 

  (iii)

Syncona Investment Management Limited; and

 

  (iv)

Syncona Limited

 

(b)

Address of principal business office or, if none, residence:

The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Synocna Limited is Arnold House, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.

 

(c)

Citizenship:

Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited’s citizenship is United Kingdom.

 

(d)

Title and class of securities:

Ordinary Shares, nominal value 0.000042 GBP per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer.

 

(e)

CUSIP No.:

There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.”

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

Page 6 of 9


   SCHEDULE 13G   
CUSIP No. 05280R 100      

 

Item 4.

The following information with respect to the ownership of Ordinary Shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G/A is provided as of December 31, 2020:

 

Reporting Persons

   Ordinary
Shares Held
Directly (1)
     Sole
Power
to Vote
or
Direct
the
Vote (1)
     Shared
Power to Vote
or Direct the
Vote (1)
     Sole
Power to
Dispose or
Direct the
Disposition
(1)
     Shared
Power to
Dispose or
Direct the
Disposition
(1)
     Amount
Beneficially
Owned (1)
     Percentage
of Class (2)
 

Syncona Portfolio Limited

     0        0        15,955,734        0        15,955,734        15,955,734        30.5

Syncona Holdings Limited

     15,955,734        0        15,955,734        0        15,955,734        15,955,734        30.5

Syncona Investment Management Limited

     0        0        15,955,734        0        15,955,734        15,955,734        30.5

Syncona Limited

     0        0        15,955,734        0        15,955,734        15,955,734        30.5

 

(1)

Consists of 12,180,333 ordinary shares and 3,775,401 American Depositary Share (“ADS”) held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer. The ordinary shares and the ADS are collectively referred to as the “Ordinary Shares”.

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned was calculated based on 52,298,876 Ordinary Shares outstanding as of September 30, 2020 as reported in the Issuer’s report on Form 6-Kfiled with the SEC on November 5, 2020.

The shares are owned directly by Syncona Portfolio Limited (“Syncona Portfolio”) and indirectly by Syncona Holdings Limited (“Syncona Holdings”) and Syncona Limited (“Syncona Limited”). Syncona Portfolio is a wholly owned subsidiary of Syncona Holdings, and Syncona Holdings is a wholly controlled subsidiary of Syncona Limited (“Syncona Limited”), a publicly-listed company. Investment and voting decisions with respect to these shares are made by Syncona Portfolio, acting upon the recommendation of an investment committee of Syncona Investment Management Limited, also a subsidiary of Syncona Holdings. Each of these entities disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Not applicable.

 

Item 8.

Identification and classification of members of the group.

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

Not applicable.

 

Item 10.

Certifications.

Not applicable.

 

Page 7 of 9


          
          

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2021

 

SYNCONA PORTFOLIO LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director
SYNCONA HOLDINGS LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director
SYNCONA INVESTMENT MANAGEMENT LIMITED
By:   /s/ John Bradshaw
Name:   John Bradshaw
Title:   CFO
SYNCONA LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director

Exhibit(s):

 

Exhibit 99.1:   

Joint Filing Statement

 

Page 8 of 9

EX-99.1

Exhibit 99.1

AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Autolus Therapeutics plc and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, as amended.

Dated: February 12, 2021

 

SYNCONA PORTFOLIO LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director
SYNCONA HOLDINGS LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director
SYNCONA INVESTMENT MANAGEMENT LIMITED
By:   /s/ John Bradshaw
Name:   John Bradshaw
Title:   CFO
SYNCONA LIMITED
By:   /s/ Robert Hutchinson
Name:   Robert Hutchinson
Title:   Director